By Fineline Cube 
China-based Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a leader in nuclear medicine (radiopharmaceuticals), announced this week that it has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The filing was jointly sponsored by China International Capital Corporation (CICC) and CITIC Securities. This move highlights the company’s ambition to expand its presence in the global radiopharmaceutical market.
Company Overview
Founded in 2005, Sinotau Pharma is recognized as the first enterprise in China to obtain approval for the marketing of innovative radiopharmaceuticals. It holds a Market Authorization Holder (MAH) production license and has successfully completed regulatory clinical trials and marketing filings for therapeutic radio-ligand therapies (RLTs). The company’s product pipeline encompasses oncology, neurodegenerative diseases, and cardiovascular diseases, with 15 assets in development.
Key Product: XTR008
Among its pipeline assets is XTR008, which is anticipated to become the first SSTR-targeted RLT approved in China. The New Drug Application (NDA) for XTR008 is currently under review in the country.
Financial Highlights
In 2024, Sinotau Pharma reported revenues of RMB 44.06 million (USD 6.1 million) and a loss of RMB 156 million (USD 21.7 million). Following a capital increase in November 2024, the company’s market valuation reached RMB 5.19 billion (USD 721.3 million).-Fineline Info & Tech